EDUCATION

Psychology
  • Yale University , New Haven , CT
Medicine
  • University of Chicago, Pritzker School of Medicine , Chicago , IL
Ph -D -
  • University of Chicago , Chicago , IL
Allergy Immunology
  • Boston Children's Hospital , Boston , Ma
Pediatrics
  • Boston Combined Residency Program , Boston , Ma
Pediatrics
  • Boston Combined Residency Program , Boston , Ma

CERTIFICATIONS

  • American Board of Allergy and Immunology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. MacGinnitie A, Kamalia R, Alvernaz L, Timmons K, Hamel V, Lafreniere A, Minsk B, Platt C, Lee P, Burke-Roberts E, Dilley M. A Quality Improvement Initiative to Increase Access to Food Challenges. Pediatr Allergy Immunol. 2018 Mar 07. View abstract
  2. MacGinnitie AJ, Young MC. The Role of Food Challenges in Clinical Practice. J Allergy Clin Immunol Pract. 2018 Mar - Apr; 6(2):353-360. View abstract
  3. Bird JA, Spergel JM, Jones SM, Rachid R, Assa'ad AH, Wang J, Leonard SA, Laubach SS, Kim EH, Vickery BP, Davis BP, Heimall J, Cianferoni A, MacGinnitie AJ, Crestani E, Burks AW. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. J Allergy Clin Immunol Pract. 2018 Mar - Apr; 6(2):476-485.e3. View abstract
  4. Akuete K, Guffey D, Israelsen RB, Broyles JM, Higgins LJ, Green TD, Naimi DR, MacGinnitie AJ, Vitalpur G, Minard CG, Davis CM. Multicenter prevalence of anaphylaxis in clinic-based oral food challenges. Ann Allergy Asthma Immunol. 2017 10; 119(4):339-348.e1. View abstract
  5. MacGinnite A. Update on Potential Therapies for IgE-Mediated Food Allergy. Curr Allergy Asthma Rep. 2017 Jan; 17(1):4. View abstract
  6. MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, Heimall J, Makhija M, Robison R, Chinthrajah RS, Lee J, Lebovidge J, Dominguez T, Rooney C, Lewis MO, Koss J, Burke-Roberts E, Chin K, Logvinenko T, Pongracic JA, Umetsu DT, Spergel J, Nadeau KC, Schneider LC. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017 Mar; 139(3):873-881.e8. View abstract
  7. Simberloff T, Parambi R, Bartnikas LM, Broyles AD, Hamel V, Timmons KG, Miller DM, Graham DA, Schneider LC, MacGinnitie AJ. Implementation of a Standardized Clinical Assessment and Management Plan (SCAMP) for Food Challenges. J Allergy Clin Immunol Pract. 2017 Mar - Apr; 5(2):335-344.e3. View abstract
  8. Levy S, Dedeoglu F, Gaffin JM, Garvey KC, Harstad E, MacGinnitie A, Rufo PA, Huang Q, Ziemnik RE, Wisk LE, Weitzman ER. A Screening Tool for Assessing Alcohol Use Risk among Medically Vulnerable Youth. PLoS One. 2016; 11(5):e0156240. View abstract
  9. Craig TJ, Schneider LC, MacGinnitie AJ. Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review. Pediatr Allergy Immunol. 2015 Sep; 26(6):537-44. View abstract
  10. Craig TJ, Li HH, Riedl M, Bernstein JA, Lumry WR, MacGinnitie AJ, Stolz LE, Biedenkapp J, Chyung Y. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2015 Mar-Apr; 3(2):206-212.e4. View abstract
  11. MacGinnitie AJ. Pediatric hereditary angioedema. Pediatr Allergy Immunol. 2014 Aug; 25(5):420-7. View abstract
  12. MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R. Use of ecallantide in pediatric hereditary angioedema. Pediatrics. 2013 Aug; 132(2):e490-7. View abstract
  13. Lumry WR, Bernstein JA, Li HH, MacGinnitie AJ, Riedl M, Soteres DF, Craig TJ, Campion M, Iarrobino R, Stolz LE, Pullman WE. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study. Allergy Asthma Proc. 2013 Mar-Apr; 34(2):155-61. View abstract
  14. Li HH, Campion M, Craig TJ, Soteres DF, Riedl M, Lumry WR, MacGinnitie AJ, Shea EP, Bernstein JA. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide. Ann Allergy Asthma Immunol. 2013 Mar; 110(3):168-72. View abstract
  15. Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2013 Mar; 110(3):184-188.e2. View abstract
  16. Jacobs TS, Jones BL, MacGinnitie AJ. Long-acting beta-agonists and the risk of intensive care unit admission in children. J Asthma. 2012 Jun; 49(5):450-5. View abstract
  17. MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics. Allergy Asthma Proc. 2012 Mar-Apr; 33(2):178-85. View abstract
  18. Ruffner MA, Finegold DN, MacGinnitie AJ. Infant with unusual food reactions. Acta Paediatr. 2011 Oct; 100(10):1289, 1394-5. View abstract
  19. McHugh BM, MacGinnitie AJ. Indoor allergen sensitization and the risk of asthma and eczema in children in Pittsburgh. Allergy Asthma Proc. 2011 Sep-Oct; 32(5):372-6. View abstract
  20. Burke S, Petrov A, Johnson J, MacGinnitie A. Successful use of ecallantide to treat a hereditary angioedema attack after failure of C1 inhibitor prophylaxis. Ann Allergy Asthma Immunol. 2011 Aug; 107(2):181-2. View abstract
  21. MacGinnitie A, Aloi F, Mishra S. Clinical characteristics of pediatric patients evaluated for primary immunodeficiency. Pediatr Allergy Immunol. 2011 Nov; 22(7):671-5. View abstract
  22. Owens G, MacGinnitie A. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J Allergy Clin Immunol. 2011 Jan; 127(1):264-5. View abstract
  23. MacGinnitie A. In utero anaphylaxis. Med Hypotheses. 2011 Jan; 76(1):70-2. View abstract
  24. He R, Kim HY, Yoon J, Oyoshi MK, MacGinnitie A, Goya S, Freyschmidt EJ, Bryce P, McKenzie AN, Umetsu DT, Oettgen HC, Geha RS. Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13. J Allergy Clin Immunol. 2009 Oct; 124(4):761-70.e1. View abstract
  25. Puglisi G, Netravali MA, MacGinnitie AJ, Bonagura VR. 11q terminal deletion disorder and common variable immunodeficiency. Ann Allergy Asthma Immunol. 2009 Sep; 103(3):267-8. View abstract
  26. Scholnicoff ET, MacGinnitie AJ, Lin PL, Darville T. Chronic granulomatous disease in an adolescent with recurrent impetigo and cholecystectomy. Pediatr Infect Dis J. 2009 Mar; 28(3):255-7. View abstract
  27. Kapadia SB, Macginnitie AJ, Shaw PH. X-linked lymphoproliferative disease in an EBV-negative patient presenting with pancytopenia. Pediatr Blood Cancer. 2008 Jun; 50(6):1296-7. View abstract
  28. MacGinnitie AJ, Walensky LD, Turvey SE, Orange JS, Bonilla FA, Silverman LB, Oettgen H. Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge. Pediatr Allergy Immunol. 2003 Oct; 14(5):409-11. View abstract
  29. MacGinnitie AJ, Geha R. X-linked lymphoproliferative disease: genetic lesions and clinical consequences. Curr Allergy Asthma Rep. 2002 Sep; 2(5):361-7. View abstract
  30. Madsen P, Anant S, Rasmussen HH, Gromov P, Vorum H, Dumanski JP, Tommerup N, Collins JE, Wright CL, Dunham I, MacGinnitie AJ, Davidson NO, Celis JE. Psoriasis upregulated phorbolin-1 shares structural but not functional similarity to the mRNA-editing protein apobec-1. J Invest Dermatol. 1999 Aug; 113(2):162-9. View abstract
  31. Anant S, Martin SA, Yu H, MacGinnitie AJ, Devaney E, Davidson NO. A cytidine deaminase expressed in the post-infective L3 stage of the filarial nematode, Brugia pahangi, has a novel RNA-binding activity. Mol Biochem Parasitol. 1997 Sep; 88(1-2):105-14. View abstract
  32. MacGinnitie AJ, Anant S, Davidson NO. Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity. J Biol Chem. 1995 Jun 16; 270(24):14768-75. View abstract
  33. Anant S, MacGinnitie AJ, Davidson NO. apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding protein. J Biol Chem. 1995 Jun 16; 270(24):14762-7. View abstract
  34. Davidson NO, Anant S, MacGinnitie AJ. Apolipoprotein B messenger RNA editing: insights into the molecular regulation of post-transcriptional cytidine deamination. Curr Opin Lipidol. 1995 Apr; 6(2):70-4. View abstract
  35. Anant S, MacGinnitie AJ, Davidson NO. The binding of apobec-1 to mammalian apo B RNA is stabilized by the presence of complementation factors which are required for post-transcriptional editing. Nucleic Acids Symp Ser. 1995; (33):99-102. View abstract